SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Okwamanje kusaphenywa ocwaningweni olubalulekile lweSigaba 2, i-CART-ddBCMA iwukwelashwa kwe-T-cell ye-Arcellx kusetshenziswa inoveli yokwenziwa ye-synthetic binder yenkampani, i-D-Domain. I-Kite ne-Arcellx bazothuthukisa ngokuhlanganyela futhi bathengise impahla ye-CART-ddBCMA e-US, futhi i-Kite izothengisa umkhiqizo ngaphandle kwase-US.
Ukwelashwa kwe-CAR T-Cell iphakathi kokwelashwa okuyimpumelelo kwezinhlobo ezithile zomdlavuza wegazi. Zingaphezu kuka-750 eziqhubekayo izivivinyo zokwelashwa in Ukwelashwa kwe-CAR T-Cell eChina okwamanje. Iziguli ezifisa ukubhalisa zingaxhumana ICancerFax inombolo yosizo yesiguli ku-WhatsApp +91 96 1588 1588 noma nge-imeyili ku info@cancerfax.com.
Mayelana ne-Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory i-myeloma eminingi (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk i-myelodysplastic syndrome, initiated in the fourth quarter of 2022.
Mayelana neKite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Mayelana neSayensi yaseGileyadi
I-Gilead Sciences, Inc. yinkampani ye-biopharmaceutical ephishekele futhi yazuza impumelelo kwezokwelapha iminyaka engaphezu kwamashumi amathathu, ngenhloso yokudala umhlaba onempilo kubo bonke abantu. Le nkampani izibophezele ekuthuthukiseni imithi emisha yokuvimbela nokwelapha izifo ezisongela ukuphila, okuhlanganisa i-HIV, i-viral hepatitis kanye nomdlavuza. IGileyadi isebenza emazweni angaphezu kuka-35 emhlabeni wonke, inendlunkulu eFoster City, eCalifornia. ISayensi yaseGileyadi yathola iKite ngo-2017.
